The objective of this study was to describe adults initiating dupilumab for AD, in terms of sociodemographics, comorbidity burden, AD treatment patterns, and persistence on dupilumab. From Truven US MarketScan data, we identified adults with AD with 1 dupilumab dispensation (Rx) between 28 March 2017 (US market launch) and 31 January 2018 with continuous enrolment during the baseline period (12 months prior to index Rx). Patients were followed from first dupilumab Rx until 31 July 2018 or disenrollment. Kaplan-Meier curves were used to estimate persistence at 6 and 12 months, using a 30-day grace period and assuming 14-day injection frequency. 1,637 adults initiated dupilumab (mean[SD] age 42.2[15.8]; 49.9% women, 94.7% commercially insured) and 53.2% had 1 atopic comorbidity (allergic rhinitis [33.7%] and asthma [26.8%] were most prevalent). AD treatments during baseline included: systemic corticosteroids (71.9%), PDE-4 inhibitors (15.8%), phototherapy (10.1%), immunosuppressants (24.7%; 10.8% cyclosporine), topical corticosteroids (81.1%). Over a mean (SD) follow-up of 287.5 (106.2) days, dupilumab persistence (95% CI) at 6 and 12 months was 92.2% (90.9-93.6%) and 78.5% (75.9-81.1%), respectively. Among patients discontinuing dupilumab, 66.9% reinitiated treatment within a mean of 111.5 (65.5) days. Most dupilumab initiators were persistent at 12 months; among those discontinuing, a majority reinitiated treatment. We conclude that 12month persistence on dupilumab in AD is higher than reported persistence for the most commonly used first-line biologic treatment for psoriasis, adalimumab (53.4% 1 ). These findings suggest patient satisfaction with dupilumab effectiveness and tolerability. 1
cm) failed at 5 months, and one lesion (3.9 cm) recurred 21 months after SBRT. Two of the 3 patients with LF received SBRT as salvage after failing metastatectomy at the same site. In the entire cohort, local control and OS did not differ based on age, gender, histology, fractionation regimen, lesion location, or size (all p>0.05). Three patients developed grade 2 chest wall toxicities; one patient had grade 2 pneumonitis. No other acute or late grade 2 toxicities were observed. Conclusion: To our knowledge, this is the first multi-institutional series reporting on SBRT for pulmonary sarcoma metastases and demonstrates that SBRT is well-tolerated with excellent local control. SBRT should be considered in these patients as an alternative to surgical resection. Prospective trials of SBRT vs. surgery are warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.